摘要
膀胱癌是泌尿系统最常见的恶性肿瘤之一,易复发,发病率正逐年增高。目前膀胱镜检查和尿细胞学检查仍是膀胱移行细胞癌(bladder transitional cell carcinoma,BTCC)诊断和随访的金标准。由于膀胱镜检查会带给患者创伤且检测费用昂贵,同时细胞学检查的敏感性低。随着分子生物学技术的发展,许多膀胱肿瘤标志物被逐步发现,因此选择高敏感性和特异性的膀胱肿瘤标志物用于肿瘤的早期诊断和治疗将具有重要的临床应用价值。本文就近年来膀胱肿瘤标志物检测的研究进展作一综述。
Bladder cancer is a common type of tumor in the urinary system, Its incidence has been increasing and the disease has a high rate of recurrence. Cystoscopy and cytology are the main methods for the diagnosis and the early detection of recurrence for bladder transitional cell carcinoma. Since cystoscopy is expensive and invasive, and although cytology is non-invasive but it is not very sensitive, many tumor makers have recently been studied in the diagnosis of the disease. So how to choose tumor makers with high sensitivity and specificity for the diagnosis of the disease so that the patients with bladder cancer could be treated at the earliest stages is important, the biomarkers may play a very important role in clinical application. In this review we discussed the development of biomarkers for bladder cancer.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2009年第7期557-561,共5页
China Oncology
关键词
膀胱肿瘤
肿瘤标记物
肿瘤
诊断
bladder cancer
tumor makers
neoplasm
diagnosis
